Article Details
Retrieved on: 2021-08-25 06:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
LUND, Sweden, Aug. 25, 2021 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological ...
Article found on: www.benzinga.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here